GI
ADCT icon

GAMMA Investing’s ADC Therapeutics ADCT Stock Holding History

GAMMA Investing’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52 Sell
49
-683
-93% -$1.99K ﹤0.01% 4121
2026
Q1 		$2.75K Buy
732
+240
+49% +$946 ﹤0.01% 3567
2025
Q4 		$1.74K Buy
+492
New +$2K ﹤0.01% 3646

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GAMMA Investing's ADCT Position: Q2 2026 in Review

GAMMA Investing reduced its ADC Therapeutics (ADCT) stake by 93% in Q2 2026, selling an estimated $1.99K and leaving 49 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #4121.

GAMMA Investing first reported a position in ADCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.75K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • GAMMA Investing held 49 shares of ADC Therapeutics worth $52 as of Q2 2026.
  • GAMMA Investing sold 683 ADC Therapeutics shares in Q2 2026, an estimated $1.99K.
  • ADC Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4121 holding.
  • GAMMA Investing first reported a position in ADC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GAMMA Investing's ADC Therapeutics position peaked at $2.75K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.